# Clinical Evaluation of the Residual Antimicrobial Activity

> **NCT04495920** · EARLY_PHASE1 · COMPLETED · sponsor: **CAGE Bio Inc.** · enrollment: 12 (actual)

## Conditions studied

- Bacterial Overgrowth

## Interventions

- **DRUG:** CGB-S-100

## Key facts

- **NCT ID:** NCT04495920
- **Lead sponsor:** CAGE Bio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-16
- **Primary completion:** 2020-07-13
- **Final completion:** 2020-07-28
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2020-08-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04495920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04495920, "Clinical Evaluation of the Residual Antimicrobial Activity". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04495920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*